These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 11398153)

  • 41. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE; Shapiro DR; Tate AC; Goldberg RB; Stein EA
    Clin Ther; 1995; 17(2):186-203. PubMed ID: 7614520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
    Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
    J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
    Koskinen P; Kovanen PT; Tuomilehto J; Manninen V
    Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM; Ordóñez-Llanos J; Jorba O; Pérez A
    Metabolism; 2004 Nov; 53(11):1516. PubMed ID: 15558848
    [No Abstract]   [Full Text] [Related]  

  • 50. Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.
    Shammas NW; Kapalis MJ; Deckert J; Harris M; Dippel EJ; Labroo A; McKinney D
    Prev Cardiol; 2003; 6(4):189-94. PubMed ID: 14605512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
    Smit JW; Jansen GH; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Orö L
    Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM; Branco MC; Pereira M; Figueiredo H; Jesus LC; de Moura JP; Ferreira MR; Serra e Silva P
    Rev Port Cardiol; 1995 Apr; 14(4):313-22, 284. PubMed ID: 7612280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP; Ganotakis ES; Spyropoulos KA; Jagroop IA; Byrne DJ; Winder AF
    Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.